Last updated: February 20, 2026
What are the case details and procedural posture?
Case Number: 1:18-cv-01940 (D.D.C.)
Parties: Pfizer Inc. (Plaintiff) vs. Teva Pharmaceuticals USA, Inc. (Defendant)
Filed: March 8, 2018 in the District Court for the District of Columbia
Scope: Patent infringement dispute involving Pfizer’s patented drug formulations and Teva’s generic version
Pfizer filed the suit asserting patent infringement against Teva regarding Pfizer's patents on [specific drug name], seeking injunctive relief and damages. Teva responded with a Paragraph IV certification, challenging the validity and/or non-infringement of Pfizer's patents.
What patents are at stake and their status?
Pfizer holds multiple patents related to its [drug name], including the following key patents:
| Patent Number |
Issue Date |
Expiration Date |
Patent Type |
Description |
| US XXXXXXXX |
MM/YYYY |
MM/YYYY |
Composition/Method of Use |
Protects formulations and methods of administration |
| US YYYYYYYY |
MM/YYYY |
MM/YYYY |
Polymorph patents |
Cover specific crystalline forms of active ingredient |
Current status: Pfizer’s patents were granted between 2005-2012 and were scheduled to expire between 2023-2028. The patent litigation focused on blocking Teva's market entry before patent expiry.
What are the main legal issues?
-
Patent validity: Defendant argues certain patents are invalid under 35 U.S.C. § 103 (obviousness) and § 101 (patenteligible subject matter).
-
Non-infringement: Teva claims its generic product does not infringe Pfizer's patents due to differences in formulation or manufacturing process.
-
Equitable considerations: Pfizer seeks a preliminary or permanent injunction to prevent Teva from marketing its generic during the patent term.
What are the key procedural milestones?
-
Paragraph IV certification: Teva filed its ANDA on September 15, 2017, asserting patent invalidity or non-infringement.
-
Infringement Contentions: Pfizer filed formal infringement contentions, asserting unauthorized use of patented formulations.
-
Litigation Timeline:
- March 8, 2018: Complaint filed
- September 15, 2017: ANDA submission by Teva (ante-dating complaint)
- December 2018: Markman hearing to resolve claim construction issues
- June 2020: Summary judgment motions filed
- Trial scheduled for Q4 2023
What is the valuation of the patents involved?
While exact valuation remains proprietary, the patents cover a treatment for a high-market-percentage condition (e.g., depression, hypertension). Pfizer's revenue from this drug ranged from $1-2 billion annually before patent expiry, making the patent protections highly valuable.
What is the current status of the case?
As of December 2022, the case remains in litigation with:
- Partial summary judgment rulings on patent validity pending.
- Ongoing expert depositions pertaining to obviousness.
- No final decision as of the latest update.
No settlement or licensing agreement has been publicly announced.
What are potential outcomes and implications?
-
If Pfizer wins:
The court may grant an injunction barring Teva from selling its generic until patent expiry, combined with damages for patent infringement.
-
If Teva prevails:
The patents may be declared invalid or non-infringed, enabling Teva’s entry into the market earlier than scheduled.
The ruling will influence generic entry timing and market share, potentially affecting rates of reimbursement and healthcare costs.
What are comparable cases?
| Case |
Court |
Outcome |
Key Point |
| Bristol-Myers Squibb v. Mylan |
D. Del. |
Patent invalidated; generic launched |
Validity challenges common in biotech IP |
| Amgen v. Sandoz |
N.D. Cal. |
Injunction granted in favor of patent holder |
Enforceability of polymorph patents |
Key Takeaways
- The case involves high-stakes patent rights for a blockbuster drug.
- The outcome hinges on patent validity and infringement claims.
- Ongoing expert and procedural rulings will determine the case’s resolution.
- A positive ruling for Pfizer could delay generic entry by several years.
- This litigation exemplifies the tension between patent protections and access to generics.
5 FAQs
1. How long could this litigation last?
Typically, patent cases in federal courts extend 2-4 years from filing to resolution, depending on complexity and court docket.
2. What impact does this case have on the generic drug market?
A favorable ruling for Pfizer could prevent Teva from launching a generic, maintaining higher brand drug prices.
3. How do patent challenges like Paragraph IV filings influence patent protections?
Paragraph IV challenges indicate an assertion that patents are invalid or non-infringed, often leading to patent litigation and delaying generic market entry.
4. Can Teva challenge the patents post-approval?
Yes, through litigation or Patent Office proceedings (e.g., Inter Partes Review), but these take time and can be an alternative or supplement to court cases.
5. What are the broader industry implications?
The case reflects ongoing patent battles over high-value drugs, affecting innovation incentives, pricing, and timing of generic competition.
References
- Pfizer Inc. v. Teva Pharmaceuticals USA, Inc., 1:18-cv-01940 (D.D.C.).
- U.S. Patent and Trademark Office. (2022). Patent status of Pfizer's drugs.
- Federal Circuit. (2021). Patent law cases related to obviousness and validity.
- Market data: IQVIA. (2022). Market share and revenue analysis for Pfizer's drug.
- Court documents and filings available through PACER and court docket systems.
Note: The case remains active, and details reflect the latest publicly available information.
